Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Utah
This study will test the hypothesis that the rapidly-acting antidepressant ketamine improves core depressive symptoms by acutely activating the brain's endogenous µ-opioid system.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18-65
DSM-5 major depressive disorder
Current moderate-to-severe, treatment-resistant, depressive episode
Patient Health Questionnaire (PHQ-9) total score ≥ 10
PHQ-9 item score ≥ 2 on "Little interest or pleasure" item
PHQ-9 item score ≥ 2 on "Feeling down, depressed, or hopeless" item
Medical documentation of depression for at least 2 months
Inadequate response to at least one adequate antidepressant medication trial in the current episode
You may not be if
Current episode duration \>5 years
Moderate-to-severe DSM-5 substance use disorder (past year)
Cognitive disorder (past year)
Post-traumatic stress disorder (past year)
Obsessive compulsive disorder (past year)
Personality disorder (past year)
Positive urine drug screen
Psychotic symptoms
Mania
Significant neurologic disorder or injury
Breastfeeding or pregnancy
Imminent suicide risk
Current use of CYP3A4 inhibitors (e.g., ketoconazole or erythromycin)
Other unstable psychiatric or medical condition requiring a higher level of care
